Company intelligence / Profile preview
BioXtek
- Ownership
- Private
- Development stage
- Other
Overview
BioXtek has developed a diversified pipeline of regenerative therapies using birth tissue-derived biologics. Their lead programs focus on wound healing and musculoskeletal repair with promising preclinical results; at least one program has reached IND approval for clinical trials. The company is also developing advanced delivery systems such as biomimetic scaffolds and hydrogels[1][4][5].
- Therapeutic areas
- Infectious DiseasesDermatologyOtherImmunologyRheumatology
- Modalities
- Exosome-based therapyMesenchymal stem cell therapyGrowth factor therapyCytokine therapyPeptides (biologic)
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on BioXtek.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioXtek.